Media

MediaPharma is an Italian biotechnology company focused on the development of novel monoclonal antibodies and antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company leverages its proprietary ADCTech platform to design next-generation therapeutics that target validated oncology pathways such as MET, EGFR, and HER3. MediaPharma's pipeline includes several candidates in the pre-clinical stage, aiming to address unmet needs in cancers with high metastatic potential and resistance to current therapies. By combining internal research with strategic academic and industrial collaborations, the company seeks to advance precision medicine in the oncology space.